Eris Lifesciences (“Eris”) announced its joint venture with Mumbai-based MJ Biopharm Pvt Ltd. (“MJ”),  Eris MJ Biopharm Ltd.,  focused on the marketing and distribution of insulins (including aspart, glargine and lispro), GLP1 agonists, and potentially other biopharma products in India.  Under the agreement, MJ will be responsible for the development, manufacturing and supply of the products to Eris MJ Biopharm Ltd.

Lupin Limited (“Lupin”) announced its entry into an exclusive distribution and marketing agreement for its proposed biosimilar of pegfilgrastim with Brazil-based Biomm SA (“Biomm”).  Under the terms of the agreement, Biomm will market and distribute Lupin’s proposed biosimilar of pegfilgrastim in Brazil.  The aBLA for Lupin’s proposed biosimilar was accepted by the U.S. FDA in June 2021.

Prestige Biopharma (“Prestige”) also announced a marketing agreement with Dr. Reddy’s Laboratories (“Dr. Reddy’s”) for its biosimilar of trastuzumab, TUZNUE, in South America and Southeast Asia.  Under the agreement, Prestige will manufacture the biosimilar in Osong, North Chungcheong Province, and Dr. Reddy’s will market TUZNUE in eight countries, including five in South America and three in Southeast Asia.